2015 Annual Meeting of the European Association for the Study of the Liver*

This downloadable slideset summarizes key studies selected by Andrew J. Muir, MD, David R. Nelson, MD, and Norah Terrault, MD, MPH, regarding the use of investigational agents for treating hepatitis C presented at the 2015 Annual Meeting of the European Association for the Study of the Liver.

In this downloadable slideset, Jordan J. Feld, MD, MPH; Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, FAASLD; and Stefan Zeuzem, MD, review key studies on currently approved HCV therapies presented at the 2015 Annual Meeting of the European Association for the Study of the Liver.

In this Expert Analysis, Jordan J. Feld, MD, MPH; David R. Nelson, MD; and Stefan Zeuzem, MD, provide a comprehensive review of the most significant data on the management of hepatitis C presented at the 2015 Annual Meeting of the European Association for the Study of the Liver.

Jordan J. Feld, MD, MPH David R. Nelson, MD Stefan Zeuzem, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: June 29, 2015 Expiration: June 28, 2016

With the highly effective DAA regimens now available for treating patients with HCV, fewer patients experience treatment failure. Could pretreatment-resistance testing help to decrease failures even further?

Jordan J. Feld, MD, MPH Released: July 28, 2015

Following the recent FDA approval of daclatasvir and the presentation of key data at the 2015 EASL meeting, our team has made several changes to our approach in managing patients with genotype 3 HCV infection.

Norah Terrault, MD, MPH Released: September 10, 2015